Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
0 hedge funds and large institutions have $0 invested in Y-mAbs Therapeutics in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.04% less ownership
Funds ownership: 0.04% → 0% (-0.04%)
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $78.3K → $0 (-$78.3K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIG
Brooklyn Investment Group
Brooklyn,
New York
|
-$75.5K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$2.86K |
YMAB Hedge Fund Activity: Q4 2025 in Review
0 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2025, worth a combined $0 — down 100% from $78.3K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of YMAB and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Brooklyn Investment Group, exiting entirely with an estimated $75.5K sold.
- 0 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2025, down from 2 in Q3 2025.
- Funds reported $0 of Y-mAbs Therapeutics stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Y-mAbs Therapeutics positions in Q4 2025 and 2 closed out, a net change of -2 holders.
- The largest Y-mAbs Therapeutics seller in Q4 2025 was Brooklyn Investment Group, an estimated $75.5K sold.
Based on aggregated 13F filings for Q4 2025.